Last reviewed · How we verify
WD-890 tablet
At a glance
| Generic name | WD-890 tablet |
|---|---|
| Sponsor | Zhejiang Wenda Pharma Technology LTD. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of WD-890 in Participants With Moderate-to-Severe Plaque Psoriasis (PHASE2)
- A Single-And Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of WD-890 Tablets in Healthy Chinese Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- WD-890 tablet CI brief — competitive landscape report
- WD-890 tablet updates RSS · CI watch RSS
- Zhejiang Wenda Pharma Technology LTD. portfolio CI